{"id":"histidine","rwe":[],"_fda":{"id":"488d78ac-3cd2-4593-8968-2992fe59bb49","set_id":"2d212e10-7e08-4aeb-b63f-dcc927897769","openfda":{"nui":["N0000175780","M0000922"],"unii":["OF5P57N2ZX","94ZLA3W45F","30KYC7MIAI","3KX376GY7L","TE7660XO1C","4QD397987E","04Y7590D77","GMW67QNF9C","TTL6G7LIWZ","AE28F7PNPL","47E5O17Y3R","9DLQ4CIU6V","452VLY9402","1EQV5MLY3D","2ZD004190S","8DUH1N11BX","42HK56048U","HG18B9YRS7"],"route":["INTRAVENOUS"],"rxcui":["831426","831430"],"spl_id":["488d78ac-3cd2-4593-8968-2992fe59bb49"],"brand_name":["Aminosyn-PF"],"spl_set_id":["2d212e10-7e08-4aeb-b63f-dcc927897769"],"package_ndc":["0990-4178-03"],"product_ndc":["0990-4178"],"generic_name":["ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, AND TYROSINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Amino Acids [CS]"],"substance_name":["ALANINE","ARGININE","ASPARTIC ACID","GLUTAMIC ACID","GLYCINE","HISTIDINE","ISOLEUCINE","LEUCINE","LYSINE ACETATE","METHIONINE","PHENYLALANINE","PROLINE","SERINE","TAURINE","THREONINE","TRYPTOPHAN","TYROSINE","VALINE"],"pharm_class_epc":["Amino Acid [EPC]"],"manufacturer_name":["ICU Medical Inc."],"application_number":["NDA019398"],"is_original_packager":[true]},"version":"4","warnings":["WARNINGS Safe, effective use of parenteral nutrition requires a knowledge of nutrition as well as clinical expertise in recognition and treatment of the complications which can occur. FREQUENT EVALUATION AND LABORATORY DETERMINATIONS ARE NECESSARY FOR PROPER MONITORING OF PARENTERAL NUTRITION. Studies should include blood sugar, serum proteins, kidney and liver function tests, electrolytes, hemogram, carbon dioxide content, serum osmolalities, blood cultures, and blood ammonia levels. Administration of amino acids in the presence of impaired renal function or gastrointestinal bleeding may augment an already elevated blood urea nitrogen. Patients with azotemia from any cause should not be infused with amino acids without regard to total nitrogen intake. Administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the solutions. Administration of amino acid solutions to a patient with hepatic insufficiency may result in plasma amino acid imbalances, hyperammonemia, prerenal azotemia, stupor and coma. Hyperammonemia is of special significance in infants , as its occurrence in the syndrome caused by genetic metabolic defects is sometimes associated, although not necessarily in a causal relationship, with mental retardation. This reaction appears to be dose-related and is more likely to develop during prolonged therapy. It is essential that blood ammonia be measured frequently in infants. Conservative doses of amino acids should be given, dictated by the nutritional status of the patient. Should symptoms of hyperammonemia develop, amino acid dosage levels should be reduced and titrated against serum ammonia levels. WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration."],"pregnancy":["Pregnancy Category C Animal reproduction studies have not been conducted with Aminosyn-PF 7%. It is also not known whether Aminosyn-PF 7% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Aminosyn-PF 7% should be given to a pregnant woman only if clearly needed."],"overdosage":["OVERDOSAGE In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS and PRECAUTIONS ."],"description":["DESCRIPTION Aminosyn ® -PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is a sterile, nonpyrogenic solution for intravenous infusion. Aminosyn ® -PF 7% is oxygen sensitive. The formulation is described below: Aminosyn-PF 7% An Amino Acid Injection — Pediatric Formula Essential Amino Acids (mg/100 mL) Isoleucine 534 Leucine 831 Lysine (acetate)* 475 Methionine 125 Phenylalanine 300 Threonine 360 Tryptophan 125 Valine 452 * Amount cited is for lysine alone and does not include the acetate salt. Nonessential Amino Acids (mg/100 mL) Alanine 490 Arginine 861 L-Aspartic Acid 370 L-Glutamic Acid 576 Glycine 270 Histidine 220 Proline 570 Serine 347 Taurine 50 Tyrosine 44 Electrolytes (mEq/L) Sodium (Na + ) (mEq/L) None Potassium (K + ) (mEq/L) None Chloride (Clˉ) (mEq/L) None Acetate (C 2 H 3 O 2 ˉ) a (mEq/L) 32.5 a From lysine acetate. Product Characteristics Protein Equivalent (Approx. grams/L) 70 Total Nitrogen (grams/L) 10.69 Osmolarity (mOsmol/L) 561 pH (range) 5.5 (5.0 to 6.5) The formulas for the individual amino acids present in Aminosyn-PF 7% are as follows: Essential Amino Acids Isoleucine, USP C 6 H 13 NO 2 Leucine, USP C 6 H 13 NO 2 Lysine Acetate, USP C 6 H 14 N 2 O 2 • CH 3 COOH Methionine, USP C 5 H 11 NO 2 S Phenylalanine, USP C 9 H 11 NO 2 Threonine, USP C 4 H 9 NO 3 Tryptophan, USP C 11 H 12 N 2 O 2 Valine, USP C 5 H 11 NO 2 Nonessential Amino Acids Alanine, USP C 3 H 7 NO 2 Glycine, USP C 2 H 5 NO 2 Arginine, USP C 6 H 14 N 4 O 2 L-Aspartic Acid C 4 H 7 NO 4 HO 2 CCH 2 CH(NH 2 )CO 2 H L-Glutamic Acid C 5 H 9 NO 4 HO 2 CCH 2 CHCH(NH 2 )CO 2 H Histidine, USP C 6 H 9 N 3 O 2 Proline, USP C 5 H 9 NO 2 Serine, USP C 3 H 7 NO 3 Taurine C 2 H 7 NO 3 S Tyrosine, USP C 9 H 11 NO 3 The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period."],"precautions":["PRECAUTIONS Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. Significant deviations from normal concentrations may require the use of additional electrolyte supplements. Strongly hypertonic nutrient solutions should be administered via an intravenous catheter placed in a central vein, preferably the superior vena cava. Care should be taken to avoid circulatory overload, particularly in patients with cardiac insufficiency. Special care must be taken when giving hypertonic dextrose to a diabetic or pre-diabetic patient. To prevent severe hyperglycemia in such patients, insulin may be required. Administration of glucose at a rate exceeding the patient's utilization rate may lead to hyperglycemia, coma, and death. The effect of infusion of amino acids, without dextrose, upon carbohydrate metabolism of children is not known at this time. It is essential to provide adequate exogenous dextrose calories concurrently with amino acids. Administration of amino acids without carbohydrates may result in the accumulation of ketone bodies in the blood. Correction of this ketonemia may be achieved by the administration of carbohydrate. Essential fatty acid deficiency (EFAD) is becoming increasingly recognized in patients on long term TPN (more than 5 days). The use of fat emulsion to provide 4 — 10% of total caloric intake as linoleic acid may prevent EFAD. Peripheral administration of Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) requires appropriate dilution and provision of adequate calories. Care should be taken to assure proper placement of the needle within the lumen of the vein. The venipuncture site should be inspected frequently for signs of infiltration. If venous thrombosis or phlebitis occurs, discontinue infusions or change infusion site and initiate appropriate treatment. Extraordinary electrolyte losses such as may occur during protracted nasogastric suction, vomiting, diarrhea, or gastrointestinal fistula drainage may necessitate additional electrolyte supplementation. Metabolic acidosis can be prevented or readily controlled by adding a portion of the cations in the electrolyte mixture as acetate salts and in the case of hyperchloremic acidosis, by keeping the total chloride content of the infusate to a minimum. Aminosyn-PF 7% contains no chloride. Aminosyn-PF 7% contains no added phosphorus. Patients, especially those with hypophosphatemia, may require the addition of phosphate. To prevent hypocalcemia, calcium supplementation should always accompany phosphate administration. To assure adequate intake, serum levels should be monitored frequently. Aminosyn-PF 7% contains no more than 25 mcg/L of aluminum. To minimize the risk of possible incompatabilities arising from mixing this solution with other additives that may be prescribed, the final infusate should be inspected for cloudiness or precipitation immediately after mixing, prior to administration, and periodically during administration. SPECIAL PRECAUTIONS FOR CENTRAL INFUSIONS ADMINISTRATION BY CENTRAL VENOUS CATHETER SHOULD BE USED ONLY BY THOSE FAMILIAR WITH THIS TECHNIQUE AND ITS COMPLICATIONS. Central vein infusion (with added concentrated carbohydrate solutions) of amino acid solutions requires a knowledge of nutrition as well as clinical expertise in recognition and treatment of complications. Attention must be given to solution preparation, administration and patient monitoring. IT IS ESSENTIAL THAT A CAREFULLY PREPARED PROTOCOL, BASED ON CURRENT MEDICAL PRACTICES, BE FOLLOWED, PREFERABLY BY AN EXPERIENCED TEAM. SUMMARY HIGHLIGHTS OF COMPLICATIONS (See also Current Medical Literature). 1. Technical The placement of a central venous catheter should be regarded as a surgical procedure. One should be fully acquainted with various techniques of catheter insertion. For details of technique and placement sites, consult the medical literature. X-ray is the best means of verifying catheter placement. Complications known to occur from the placement of central venous catheters are pneumothorax, hemothorax, hydrothorax, artery puncture and transection, injury to the brachial plexus, malposition of the catheter, formation of arteriovenous fistula, phlebitis, thrombosis and air and catheter emboli. 2. Septic The constant risk of sepsis is present during administration of total parenteral nutrition. It is imperative that the preparation of the solution and the placement and care of catheters be accomplished under strict aseptic conditions. Solutions should ideally be prepared in the hospital pharmacy under a laminar flow hood using careful aseptic technique to avoid inadvertent touch contamination. Solutions should be used promptly after mixing. Storage should be under refrigeration and limited to a brief period of time, preferably less than 24 hours. Administration time for a single container and set should never exceed 24 hours. 3. Metabolic The following metabolic complications have been reported with TPN administration: Metabolic acidosis and alkalosis, hypophosphatemia, hypocalcemia, osteoporosis, hyperglycemia and glycosuria, rebound hypoglycemia, osmotic diuresis and dehydration, elevated liver enzymes, hypo- and hypervitaminosis, electrolyte imbalances and hyperammonemia in children. Frequent evaluations are necessary especially during the first few days of therapy to prevent or minimize these complications. Administration of glucose at a rate exceeding the patient's utilization rate may lead to hyperglycemia, coma and death. CLINICAL EVALUATION AND LABORATORY DETERMINATIONS, AT THE DISCRETION OF THE ATTENDING PHYSICIAN ARE NECESSARY FOR PROPER MONITORING DURING ADMINISTRATION. Do not withdraw venous blood for blood chemistries through the peripheral infusion site, as interference with estimations of nitrogen-containing substances may occur. Blood studies should include glucose, urea nitrogen, serum electrolytes, ammonia, cholesterol, acid-base balance, serum proteins, kidney and liver function tests, osmolarity and hemogram. White blood count and blood cultures are to be determined if indicated. Urinary osmolality and glucose should be determined as necessary. Pregnancy Category C Animal reproduction studies have not been conducted with Aminosyn-PF 7%. It is also not known whether Aminosyn-PF 7% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Aminosyn-PF 7% should be given to a pregnant woman only if clearly needed."],"how_supplied":["HOW SUPPLIED NDC No. Concentration Container (mL) 0409-4178-03 Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection - 500 0990-4178-03 pediatric formula) ICU Medical is transitioning NDC codes from the \"0409\" to a \"0990\" labeler code. Both NDC codes are expected to be in the market for a period of time. Store at 20 to 25ºC (68 to 77ºF). [See USP Controlled Room Temperature.] Protect from freezing. Avoid exposure to light. Revised: August, 2018 EN-4682 ICU Medical, Inc., Lake Forest, Illinois, 60045 USA"],"effective_time":"20251017","adverse_reactions":["ADVERSE REACTIONS Local reactions consisting of erythema, phlebitis and thrombosis at the infusion site have occurred with peripheral intravenous infusion of amino acids particularly if other substances, such as antibiotics, are also administered through the same site. In such cases the infusion site should be changed promptly to another vein. Use of large peripheral veins, inline filters, and slowing the rate of infusion may reduce the incidence of local venous irritation. Electrolyte additives should be spread throughout the day. Irritating additive medications may need to be injected at another venous site. Generalized flushing, fever and nausea also have been reported during peripheral infusions of amino acid solutions. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary."],"contraindications":["CONTRAINDICATIONS Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is contraindicated in patients with untreated anuria, hepatic coma, inborn errors of amino acid metabolism (including those involving branched chain amino acid metabolism such as maple syrup urine disease and isovaleric acidemia), or hypersensitivity to one or more amino acids present in the solution."],"description_table":["
Aminosyn-PF 7%An Amino Acid Injection — Pediatric Formula
Essential Amino Acids (mg/100 mL)
Isoleucine534
Leucine831
Lysine (acetate)*475
Methionine125
Phenylalanine300
Threonine360
Tryptophan125
Valine452
","
Nonessential Amino Acids (mg/100 mL)
Alanine490
Arginine861
L-Aspartic Acid370
L-Glutamic Acid576
Glycine270
Histidine220
Proline570
Serine347
Taurine50
Tyrosine44
","
Electrolytes (mEq/L)
Sodium (Na+) (mEq/L)None
Potassium (K+) (mEq/L)None
Chloride (Clˉ) (mEq/L)None
Acetate (C2H3O2ˉ)a (mEq/L)32.5
","
Product Characteristics
Protein Equivalent (Approx. grams/L)70
Total Nitrogen (grams/L)10.69
Osmolarity (mOsmol/L)561
pH (range)5.5 (5.0 to 6.5)
","
Essential Amino Acids
Isoleucine, USPC6H13NO2
Leucine, USPC6H13NO2
Lysine Acetate, USPC6H14N2O2 • CH3COOH
Methionine, USPC5H11NO2S
Phenylalanine, USPC9H11NO2
Threonine, USPC4H9NO3
Tryptophan, USPC11H12N2O2
Valine, USPC5H11NO2
","
Nonessential Amino Acids
Alanine, USPC3H7NO2
Glycine, USPC2H5NO2
Arginine, USPC6H14N4O2
L-Aspartic AcidC4H7NO4
HO2CCH2CH(NH2)CO2H
L-Glutamic AcidC5H9NO4
HO2CCH2CHCH(NH2)CO2H
Histidine, USPC6H9N3O2
Proline, USPC5H9NO2
Serine, USPC3H7NO3
TaurineC2H7NO3S
Tyrosine, USPC9H11NO3
"],"precautions_table":["
SPECIAL PRECAUTIONS FOR CENTRAL INFUSIONS
ADMINISTRATION BY CENTRAL VENOUS CATHETER SHOULD BE USED ONLY BY THOSE FAMILIAR WITH THIS TECHNIQUE AND ITS COMPLICATIONS.
"],"how_supplied_table":["
NDC No.ConcentrationContainer (mL)
0409-4178-03Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection -500
0990-4178-03pediatric formula)
"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Aminosyn-PF 7% Sulfite-Free, (an amino acid injection — pediatric formula) contains a mixture of essential and nonessential amino acids as well as taurine. The amino acid composition has been specifically formulated to provide a well-tolerated nitrogen source for nutritional support and therapy for infants and young children. When administered in conjunction with a cysteine hydrochloride additive, Aminosyn-PF 7% results in plasma amino acid concentrations approximating a profile consistent with that of a breast-fed infant. The rationale for Aminosyn-PF 7% is based on the observation of inadequate levels of essential amino acids in the plasma of infants receiving total parenteral nutrition (TPN) using conventional amino acid solutions. Clinical studies in infants who required TPN therapy showed that infusion of Aminosyn-PF 7% resulted in plasma amino acid concentrations approximating those of normal breast or formula fed infants. In addition, weight gains, nitrogen balance, and serum protein concentrations were consistent with an improving nutritional status. When infused with hypertonic dextrose as a calorie source, supplemented with cysteine hydrochloride, electrolytes, vitamins, and minerals, Aminosyn-PF 7% provides TPN for infants and young children, with the exception of essential fatty acids. It is thought that the acetate from lysine acetate under the conditions of parenteral nutrition, does not impact net acid-base balance when renal and respiratory functions are normal. Clinical evidence seems to support this thinking; however, confirmatory experimental evidence is not available. The amounts of sodium and acetate in Aminosyn-PF 7% are not of clinical significance. The addition of a cysteine hydrochloride additive will contribute to the chloride load. The electrolyte content of any additives that are introduced should be carefully considered and included in input computations. The human newborn conjugates bile with taurine which becomes the primary method of biliary excretion. Taurine deficiency because of its effect on bile salt conjugation and, therefore, on bile salt flow may be of major importance in the genesis of cholestasis. Taurine has also been shown to play a role in central nervous system development."],"indications_and_usage":["INDICATIONS AND USAGE Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is indicated for the nutritional support of infants (including those of low birth weight) and young children requiring TPN via either central or peripheral infusion routes. Parenteral nutrition with Aminosyn-PF 7% is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young children where (1) the alimentary tract by the oral gastrostomy, or jejunostomy route, cannot or should not be used or adequate protein intake is not feasible by these routes, (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. Dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutrition support, and vein tolerance. See DOSAGE AND ADMINISTRATION for additional information. Central Venous Infusion Central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis in hypercatabolic or severely depleted infants or those requiring long-term parenteral nutrition. Peripheral Parenteral Nutrition For moderately catabolic or depleted patients in whom the central venous route is not indicated, diluted amino acid solutions mixed with 5 to 10% dextrose solutions may be infused by peripheral vein, supplemented, if desired, with fat emulsion."],"spl_unclassified_section":["AN AMINO ACID INJECTION - PEDIATRIC FORMULA Flexible Plastic Container Rx only"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION The total daily dose of the solution depends on the daily protein requirements and on the patient's metabolic and clinical response. Pediatric requirements for parenteral nutrition are constrained by the greater relative fluid requirements of the infant and greater caloric requirements per kilogram than in the adult. The recommended intravenous dose of Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is up to 2.5 g amino acid/kg/day for infants up to 10 kg. For infants and children larger than 10 kg, the total daily dose of amino acids should be up to 25 g amino acids/day for the first 10 kg of body weight plus 1 to 1.25 g amino acid for each kg of body weight over 10 kg. Initial amino acid dosage levels of 1 g/kg/day may be increased gradually in increments of 0.5 g/kg/day to approximate desired intake levels. Aminosyn-PF 7% should be diluted with dextrose prior to use. Nonprotein calories should constitute approximately 100 to 130 kcal/kg/day. Part of the nonprotein caloric requirement may be provided as lipid emulsion administered concurrently to provide up to 60% of daily calories at a dose not to exceed 4 g fat/kg/day. Fluid intake for the infant receiving central venous TPN should be approximately 125 mL/kg/day (range: 100 to 175 mL/kg/day), depending on the clinical condition of the patient. Premature infants with respiratory distress syndrome suspected of having a patent ductus arteriosus should be given fluids more cautiously. Cysteine is considered to be an essential amino acid for infants, especially preterm infants with potentially immature enzyme pathways. Therefore, addition of a cysteine supplement to the TPN admixture is recommended. The intake of cysteine by the preterm infant ingesting maternal milk is approximately 78 mg/kg/day. The suggested intravenous dosage level for Cysteine Hydrochloride Injection, USP is 500 mg (10 mL) for every 12.5 g (179 mL) of Aminosyn-PF 7% administered (see package insert for Cysteine Hydrochloride Injection, USP). In order to avoid potential insolubility of cysteine hydrochloride in admixtures, the foregoing concentration should not be exceeded. In many patients, provision of adequate calories in the form of hypertonic dextrose may require the administration of exogenous insulin to prevent hyperglycemia and glycosuria. To prevent rebound hypoglycemia, a solution containing 5% dextrose should be administered when hypertonic dextrose solutions are abruptly discontinued. SERUM ELECTROLYTES SHOULD BE MONITORED FREQUENTLY. Electrolytes may be added to the nutrient solution as indicated by the patient's clinical condition and laboratory determinations of plasma values. Major electrolytes are sodium, chloride, potassium, phosphate, magnesium and calcium. Daily administration of intravenous vitamin supplements including a complete complement of fat and water-soluble vitamins is required. Trace metal additives including zinc, copper, manganese, and chromium should also be provided, especially when long-term parenteral therapy is anticipated. Calcium and phosphorus are added to the solution as indicated. Potentially incompatible ions such as calcium and phosphate may be added to alternate infusate bottles to avoid precipitation. In patients with hyperchloremic or other metabolic acidosis, sodium and potassium may be added as the acetate or lactate salts to provide bicarbonate alternates. Bicarbonate should not be administered during infusion of the nutritional solution unless deemed absolutely necessary. Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store. To ensure the precise delivery of the small volumes of fluid necessary for total parenteral nutrition in infants, accurately calibrated and reliable infusion systems should be used. Central Venous Nutrition Hypertonic mixtures of amino acids and dextrose may be safely administered by continuous infusion through a central venous catheter with the tip located in the superior vena cava. Initial infusion rates should be slow, and gradually increased to the recommended 60-125 mL per kilogram body weight per day. If administration rate should fall behind schedule, no attempt to \"catch up\" to planned intake should be made. In addition to meeting protein needs, the rate of administration, particularly during the first few days of therapy, is governed by the patient's glucose tolerance. Daily intake of amino acids and dextrose should be increased gradually to the maximum required dose as indicated by frequent determinations of glucose levels in blood and urine. Peripheral Parenteral Nutrition For patients in whom the central venous route is not indicated and who can consume adequate calories enterally, Aminosyn-PF 7% may be administered by peripheral vein with parenteral nonprotein calories. The concentration of dextrose in the final admixture is 5 to 10%, and simultaneous administration of lipid emulsion is recommended both as a calorie source and to attenuate the potentially irritating effects of the hypertonic nutritional admixture. Fat emulsion may comprise up to 60% of the daily caloric intake at a dosage level not to exceed 4 g fat/kg/day. It is essential that peripheral infusion be accompanied by adequate caloric intake. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. COLOR VARIATION FROM PALE YELLOW TO YELLOW IS NORMAL AND DOES NOT ALTER EFFICACY. WARNING: Do not use flexible container in series connections."],"spl_product_data_elements":["Aminosyn-PF ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, and TYROSINE ISOLEUCINE ISOLEUCINE LEUCINE LEUCINE LYSINE ACETATE LYSINE METHIONINE METHIONINE PHENYLALANINE PHENYLALANINE THREONINE THREONINE TRYPTOPHAN TRYPTOPHAN VALINE VALINE ALANINE ALANINE ARGININE ARGININE ASPARTIC ACID ASPARTIC ACID GLUTAMIC ACID GLUTAMIC ACID GLYCINE GLYCINE HISTIDINE HISTIDINE PROLINE PROLINE SERINE SERINE TAURINE TAURINE TYROSINE TYROSINE WATER"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 500 mL Bag Label 500 mL NDC 0990-4178-03 Aminosyn ® -PF 7% Sulfite-Free AN AMINO ACID INJECTION – PEDIATRIC FORMULA EACH 100 mL CONTAINS: TOTAL AMINO ACIDS APPROX. 7 g. ESSENTIAL AMINO ACIDS/100 mL : ISOLEUCINE 534 mg; LEUCINE 831 mg; LYSINE (AS ACETATE SALT) 475 mg; METHIONINE 125 mg; PHENYLALANINE 300 mg; THREONINE 360 mg; TRYPTOPHAN 125 mg; VALINE 452 mg. NONESSENTIAL AMINO ACIDS/100 mL: TYROSINE 44 mg; ALANINE 490 mg; ARGININE 861 mg; GLYCINE 270 mg; PROLINE 570 mg; HISTIDINE 220 mg; SERINE 347 mg; L-GLUTAMIC ACID 576 mg; L-ASPARTIC ACID 370 mg; TAURINE 50 mg. ELECTROLYTES (mEq/LITER): ACETATE 32.5. pH 5.5 (5.0 to 6.5) 561 mOsmol/LITER SPECIFIC GRAVITY = 1.02 ADDITIVES MAY BE INCOMPATIBLE. CONSULT WITH PHARMACIST, IF AVAILABLE. WHEN INTRODUCING ADDITIVES, USE ASEPTIC TECHNIQUE, MIX THOROUGHLY AND DO NOT STORE. SINGLE DOSE CONTAINER. CONTAINS NO BACTERIOSTAT. DISCARD UNUSED PORTION. FOR I.V. USE. USUAL DOSAGE: SEE INSERT. STERILE, NONPYROGENIC. STORE AT 20 TO 25°C (68 TO 77°F). [SEE USP CONTROLLED ROOM TEMPERATURE.] AVOID EXCESSIVE HEAT. PROTECT FROM FREEZING. AVOID EXPOSURE TO LIGHT. USE ONLY IF SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED. MUST NOT BE USED IN SERIES CONNECTIONS. RX ONLY IM-4405 3 v CONTAINS DEHP icumedical ICU Medical, Inc., Lake Forest, Illinois, 60045, USA PRINCIPAL DISPLAY PANEL - 500 mL Bag Label","PRINCIPAL DISPLAY PANEL - 500 mL Overwrap Label TO OPEN – TEAR AT NOTCH 500 mL NDC 0990-4178-03 Aminosyn ® -PF 7% Sulfite-Free AN AMINO ACID INJECTION — PEDIATRIC FORMULA Each 100 mL contains: Total amino acids approx. 7 g. Essential Amino Acids/100 mL: Isoleucine 534 mg; leucine 831 mg; lysine (as acetate salt) 475 mg; methionine 125 mg; phenylalanine 300 mg; threonine 360 mg; tryptophan 125 mg; valine 452 mg. Nonessential Amino Acids/100 mL: Tyrosine 44 mg; alanine 490 mg; arginine 861 mg; glycine 270 mg; proline 570 mg; histidine 220 mg; serine 347 mg; L-glutamic acid 576 mg; L-aspartic acid 370 mg; taurine 50 mg. Electrolytes (mEq/Liter): Acetate 32.5. 561 mOsmol/Liter pH 5.5 (5.0 to 6.5) Specific Gravity = 1.02 Single dose container. The overwrap is a moisture and oxygen barrier. Do not remove unit from overwrap until ready for use. Visually inspect overwrap for tears or holes. Discard unit if overwrap is damaged. Use unit promptly when overwrap is opened. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard solution as sterility may be impaired. COLOR VARIATION FROM PALE YELLOW TO YELLOW IS NORMAL AND DOES NOT ALTER EFFICACY. Rx only 7 OTHER icumedical F WR-0544 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA PRINCIPAL DISPLAY PANEL - 500 mL Overwrap Label"]},"tags":[{"label":"histidine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Large neutral amino acids transporter small subunit 1","category":"target"},{"label":"SLC7A5","category":"gene"},{"label":"Dental","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Paste","category":"form"},{"label":"Active","category":"status"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE","source":"FDA FAERS","actionTaken":"50 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"42 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"39 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"36 reports"},{"date":"","signal":"CHILLS","source":"FDA FAERS","actionTaken":"35 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"35 reports"},{"date":"","signal":"NO ADVERSE EVENT","source":"FDA FAERS","actionTaken":"30 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"28 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"24 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"24 reports"}],"commonSideEffects":[{"effect":"Foetal growth restriction","drugRate":"","severity":"common","_validated":false,"_confidence":0.3}],"contraindications":["Untreated anuria","Hepatic coma","Inborn errors of amino acid metabolism, including maple syrup urine disease and isovaleric acidemia","Hypersensitivity to one or more amino acids in the solution"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=HISTIDINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:31:43.117040+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Histidine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:31:50.017705+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:32:23.063225+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:31:48.471081+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:31:42.243161+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HISTIDINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:31:48.921390+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:31:36.012751+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:31:36.012778+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:32:16.239036+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:31:36.012783+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:31:50.414735+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1256578/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:31:49.634601+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS Local reactions consisting of erythema, phlebitis and thrombosis at the infusion site have occurred with peripheral intravenous infusion of amino acids particularly if other substances, such as antibiotics, are also administered through the same site. In such cases the infusion site should be changed promptly to another vein. Use of large peripheral veins, inline filters, and slowing the rate of infusion may reduce the incidence of local venous irritation. Electrolyte additives","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:31:53.379657+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:31:56.975427+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA019398","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:31:36.012787+00:00"}},"allNames":"l-histidine","offLabel":[],"synonyms":["L-Histidine","histidine"],"timeline":[],"aiSummary":"L-Histidine is a marketed nutritional support for infants and young children, currently without a specified revenue figure but with a key composition patent expiring in 2028. Its primary competitive advantage lies in its mechanism of action, which involves transport into cells via the Large neutral amino acids transporter small subunit 1, a unique pathway among its competitors. The primary risk to L-Histidine's market position is the presence of off-patent alternatives such as gabapentin and leucine, which may offer cost-effective substitutes for some applications.","approvals":[{"date":"","orphan":false,"company":"","regulator":"FDA"}],"brandName":"L-Histidine","ecosystem":[],"mechanism":{"target":"Large neutral amino acids transporter small subunit 1","novelty":"First-in-class","targets":[{"gene":"SLC7A5","source":"DrugCentral","target":"Large neutral amino acids transporter small subunit 1","protein":"Large neutral amino acids transporter small subunit 1"}],"modality":"Small Molecule","drugClass":"Amino Acid [EPC]","explanation":"","oneSentence":"","technicalDetail":"L-Histidine is a substrate for the Large neutral amino acids transporter small subunit 1 (LAT1), a transmembrane protein that facilitates the uptake of neutral amino acids into cells."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Histidine","title":"Histidine","extract":"Histidine (symbol His or H) is an essential amino acid that is used in the biosynthesis of proteins. It contains an α-amino group (which is in the protonated –NH3+ form under biological conditions), a carboxylic acid group (which is in the deprotonated –COO− form under biological conditions), and an imidazole side chain (which is partially protonated), classifying it as a positively charged amino acid at physiological pH. Initially thought essential only for infants, it has now been shown in longer-term studies to be essential for adults also. It is encoded by the codons CAU and CAC."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1377","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=HISTIDINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HISTIDINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Histidine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T13:51:54.399743","_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T01:32:23.063568+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"gabapentin","drugSlug":"gabapentin","fdaApproval":"1993-12-30","genericCount":47,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"leucine","drugSlug":"leucine","fdaApproval":"","relationship":"same-target"},{"drugName":"levodopa","drugSlug":"levodopa","fdaApproval":"1970-06-04","patentExpiry":"Oct 21, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"phenylalanine","drugSlug":"phenylalanine","fdaApproval":"","relationship":"same-target"},{"drugName":"pregabalin","drugSlug":"pregabalin","fdaApproval":"2004-12-30","patentExpiry":"Nov 2, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"tyrosine","drugSlug":"tyrosine","fdaApproval":"","relationship":"same-target"},{"drugName":"valine","drugSlug":"valine","fdaApproval":"","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"histidine","indications":{"approved":[{"id":"histidine-nutritional-support-for-infant","name":"Nutritional Support for Infants and Young Children","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Infants (including low birth weight) and young children","pivotalTrial":null,"restrictions":[],"patientPopulation":"Infants (including low birth weight) and young children","diagnosticRequired":null,"brandNameForIndication":"L-Histidine"},{"id":"histidine-prevent-nitrogen-and-weight-lo","name":"Prevent Nitrogen and Weight Loss","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Infants and young children with conditions affecting protein intake or requirements","pivotalTrial":null,"restrictions":[],"patientPopulation":"Infants and young children with conditions affecting protein intake or requirements","diagnosticRequired":null,"brandNameForIndication":"L-Histidine"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"gabapentin","brandName":"gabapentin","genericName":"gabapentin","approvalYear":"1993","relationship":"same-target"},{"drugId":"leucine","brandName":"leucine","genericName":"leucine","approvalYear":"","relationship":"same-target"},{"drugId":"levodopa","brandName":"levodopa","genericName":"levodopa","approvalYear":"1970","relationship":"same-target"},{"drugId":"phenylalanine","brandName":"phenylalanine","genericName":"phenylalanine","approvalYear":"","relationship":"same-target"},{"drugId":"pregabalin","brandName":"pregabalin","genericName":"pregabalin","approvalYear":"2004","relationship":"same-target"},{"drugId":"tyrosine","brandName":"tyrosine","genericName":"tyrosine","approvalYear":"","relationship":"same-target"},{"drugId":"valine","brandName":"valine","genericName":"valine","approvalYear":"","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT01915212","phase":"PHASE1","title":"Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-09-26","conditions":["Healthy Volunteers"],"enrollment":69,"completionDate":"2017-03-06"},{"nctId":"NCT07489430","phase":"PHASE2","title":"DaxibotulinumtoxinA for Blepharospasm","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-07-01","conditions":["Blepharospasm of Both Eyelids","Blepharospasm of Left Eyelid","Blepharospasm of Right Eyelid","Blepharospasm, Benign Essential","Blepharospasm"],"enrollment":20,"completionDate":"2028-12-31"},{"nctId":"NCT05681884","phase":"PHASE2","title":"Safety and Efficacy of Faricimab in Patients With NPDR","status":"COMPLETED","sponsor":"Greater Houston Retina Research","startDate":"2023-05-16","conditions":["Non-Proliferative Diabetic Retinopathy"],"enrollment":179,"completionDate":"2026-02-26"},{"nctId":"NCT06604065","phase":"PHASE1","title":"Essential Amino Acids and Parkinsons Disease","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2026-03-09","conditions":["Parkinson Disease"],"enrollment":0,"completionDate":"2026-03-09"},{"nctId":"NCT07459504","phase":"PHASE2","title":"SMART Diets for MASLD","status":"NOT_YET_RECRUITING","sponsor":"Corewell Health West","startDate":"2026-04-26","conditions":["Metabolic-dysfunction Associated Steatotic Liver Disease"],"enrollment":102,"completionDate":"2030-12-26"},{"nctId":"NCT07451496","phase":"NA","title":"PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS)","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-09-29","conditions":["Ageing"],"enrollment":20,"completionDate":"2026-06-30"},{"nctId":"NCT05854381","phase":"PHASE1","title":"To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-09-19","conditions":["HIV I Infection"],"enrollment":93,"completionDate":"2025-11-19"},{"nctId":"NCT05967299","phase":"PHASE1","title":"Study of Intravenous ZMA001 in Healthy Subjects","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2023-11-27","conditions":["Pulmonary Arterial Hypertension PAH"],"enrollment":96,"completionDate":"2027-11-30"},{"nctId":"NCT05414032","phase":"PHASE2","title":"Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-07-12","conditions":["Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)"],"enrollment":102,"completionDate":"2028-07"},{"nctId":"NCT06016387","phase":"PHASE2","title":"Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-11-25","conditions":["HER2-positive Breast Cancer","LMD"],"enrollment":30,"completionDate":"2028-10-05"},{"nctId":"NCT07424378","phase":"PHASE4","title":"Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-02","conditions":["Frostbite"],"enrollment":66,"completionDate":"2028-11"},{"nctId":"NCT05440422","phase":"PHASE2","title":"The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD","status":"RECRUITING","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2023-12-07","conditions":["Systemic Lupus Erythematosus","Cardiovascular Disease","Premature Atherosclerosis"],"enrollment":45,"completionDate":"2027-08-02"},{"nctId":"NCT06487546","phase":"NA","title":"Repletion of Ergothioneine in Patients With Kidney Failure","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-04-01","conditions":["Esrd"],"enrollment":100,"completionDate":"2029-12-01"},{"nctId":"NCT05082259","phase":"PHASE1","title":"ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2022-03-02","conditions":["Advanced Cancer","Cervical Cancer","Triple Negative Breast Cancer"],"enrollment":61,"completionDate":"2026-03-16"},{"nctId":"NCT07377253","phase":"PHASE1","title":"First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers.","status":"NOT_YET_RECRUITING","sponsor":"Giuseppe Pantaleo","startDate":"2026-01-01","conditions":["The Tick-borne Encephalitis Virus (TBEV)"],"enrollment":18,"completionDate":"2026-10-31"},{"nctId":"NCT07363395","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Alcamena Stem Cell Therapeutics","startDate":"2026-01","conditions":["Neuropathic Pain"],"enrollment":72,"completionDate":"2026-12"},{"nctId":"NCT05002998","phase":"PHASE4","title":"TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-09-16","conditions":["Thyroid Eye Disease"],"enrollment":313,"completionDate":"2025-12-19"},{"nctId":"NCT05428007","phase":"PHASE2","title":"Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-02-02","conditions":["Melanoma","Unresectable Melanoma"],"enrollment":105,"completionDate":"2028-02"},{"nctId":"NCT07197762","phase":"PHASE4","title":"MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-11-04","conditions":["Neisseria Meningitidis"],"enrollment":125,"completionDate":"2026-12"},{"nctId":"NCT06414330","phase":"PHASE3","title":"Ringer Acetate Based Modified Del Nido Cardioplegia Solution Versus HTK Solution Cardioplegia Solution in Cardiac Surgery","status":"COMPLETED","sponsor":"Assiut University","startDate":"2024-06-01","conditions":["Cardiac Ischemia"],"enrollment":124,"completionDate":"2025-12-01"},{"nctId":"NCT06717919","phase":"PHASE4","title":"HOPE Against Cancer Recurrence in HCC","status":"RECRUITING","sponsor":"Philipp Dutkowski","startDate":"2025-08-01","conditions":["Liver Transplantation","HCC","Oncological Outcomes"],"enrollment":220,"completionDate":"2028-01-31"},{"nctId":"NCT04347239","phase":"PHASE2","title":"Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19","status":"COMPLETED","sponsor":"CytoDyn, Inc.","startDate":"2020-04-16","conditions":["Coronavirus Disease 2019"],"enrollment":484,"completionDate":"2022-06-15"},{"nctId":"NCT05400733","phase":"NA","title":"Prandial Metabolic Phenotype in Adults","status":"RECRUITING","sponsor":"Texas A&M University","startDate":"2022-06-24","conditions":["Protein Metabolism"],"enrollment":50,"completionDate":"2026-09"},{"nctId":"NCT06799494","phase":"PHASE4","title":"HPV Vaccine Reduced Dose","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-08-06","conditions":["HPV"],"enrollment":100,"completionDate":"2028-09"},{"nctId":"NCT05782361","phase":"PHASE1","title":"POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2023-05-03","conditions":["Advanced Cancer","Non Small Cell Lung Cancer"],"enrollment":19,"completionDate":"2029-01-09"},{"nctId":"NCT06172127","phase":"PHASE2","title":"PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-07-22","conditions":["HER2-positive Breast Cancer"],"enrollment":165,"completionDate":"2029-05"},{"nctId":"NCT06290505","phase":"PHASE2","title":"A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study","status":"RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-12-08","conditions":["Esophageal Cancer"],"enrollment":54,"completionDate":"2029-07-31"},{"nctId":"NCT04870333","phase":"PHASE2,PHASE3","title":"PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2021-02-19","conditions":["Covid19"],"enrollment":2240,"completionDate":"2025-04-16"},{"nctId":"NCT03641404","phase":"PHASE1,PHASE2","title":"Investigating the Efficacy of Ergothioneine to Delay Cognitive Decline (Pilot)","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2019-08-01","conditions":["Mild Cognitive Impairment"],"enrollment":19,"completionDate":"2023-12-31"},{"nctId":"NCT05562310","phase":"NA","title":"Phenylalanine, Methionine and Histidine Requirements in TPN Fed Neonates","status":"RECRUITING","sponsor":"The Hospital for Sick Children","startDate":"2023-04-02","conditions":["Stable Neonates","Receiving Total Parenteral Nutrition (TPN)"],"enrollment":60,"completionDate":"2027-09-02"},{"nctId":"NCT06579391","phase":"NA","title":"Targeted Nutritional Supplement After Lumbar Spine Surgery: A Randomized, Placebo-Controlled, Double-Blind Trial","status":"WITHDRAWN","sponsor":"University of California, Irvine","startDate":"2025-01","conditions":["Lumbar Spinal Stenosis"],"enrollment":0,"completionDate":"2026-07"},{"nctId":"NCT06332274","phase":"PHASE3","title":"tislelizUMaB in canceR Patients With molEcuLar residuaL Disease","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-04-16","conditions":["Cancer","Lung Cancer","Colo-rectal Cancer","Pancreas Cancer","Soft Tissue Sarcoma"],"enrollment":717,"completionDate":"2030-04"},{"nctId":"NCT06169826","phase":"PHASE4","title":"Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2025-04","conditions":["Alzheimer Disease"],"enrollment":0,"completionDate":"2026-04"},{"nctId":"NCT06377631","phase":"NA","title":"Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity","status":"COMPLETED","sponsor":"Fundació Eurecat","startDate":"2024-06-07","conditions":["Visceral Obesity","Non-alcoholic Fatty Liver","Postmenopausal"],"enrollment":50,"completionDate":"2025-04-08"},{"nctId":"NCT06431633","phase":"PHASE3","title":"Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2025-02-04","conditions":["Lung Diseases","Carcinoma, Non-Small-Cell Lung","Resectable Lung Non-Small Cell Carcinoma"],"enrollment":129,"completionDate":"2031-11-30"},{"nctId":"NCT05190432","phase":"NA","title":"Taxifolin/ergothioneine and Immune Biomarkers in Healthy Volunteers (TaxEr)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southampton","startDate":"2021-11-10","conditions":["Antioxidative Stress","Cold","Influenza","Aging","Inflammation"],"enrollment":90,"completionDate":"2025-07"},{"nctId":"NCT02947750","phase":"PHASE2","title":"Neurovascular Transduction During Exercise in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Emory University","startDate":"2016-10","conditions":["Renal Insufficiency, Chronic"],"enrollment":150,"completionDate":"2026-01"},{"nctId":"NCT06819709","phase":"NA","title":"The Effects of a Botanical Moisturizer, an Oral Supplement, and an Unscented Soap on Eczema and Itch","status":"COMPLETED","sponsor":"Codex Labs Corporation","startDate":"2024-04-15","conditions":["Atopic Dermatitis (Eczema)"],"enrollment":35,"completionDate":"2024-09-02"},{"nctId":"NCT02780219","phase":"NA","title":"Chronic Obstructive Pulmonary Disorder and Acute Exercise","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2016-02-04","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":57,"completionDate":"2020-03-06"},{"nctId":"NCT06801951","phase":"NA","title":"Oral Supplement and Acute Resistance Exercise","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2017-12-11","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":16,"completionDate":"2020-02-27"},{"nctId":"NCT05057897","phase":"PHASE4","title":"A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2022-01-31","conditions":["COVID-19, SARS-CoV-2"],"enrollment":34,"completionDate":"2023-04-19"},{"nctId":"NCT06524947","phase":"PHASE3","title":"Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2024-07-27","conditions":["Acute Gastroenteropathy Due to Norovirus"],"enrollment":6600,"completionDate":"2027-03-28"},{"nctId":"NCT06094140","phase":"PHASE2","title":"NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2022-05-20","conditions":["Pancreatic Cancer"],"enrollment":20,"completionDate":"2026-06"},{"nctId":"NCT04722003","phase":"PHASE2","title":"Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-01","conditions":["Gonorrhoea"],"enrollment":52,"completionDate":"2023-10-02"},{"nctId":"NCT04120883","phase":"PHASE1,PHASE2","title":"Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)","status":"TERMINATED","sponsor":"University of Michigan","startDate":"2020-02-25","conditions":["Retinitis Pigmentosa"],"enrollment":8,"completionDate":"2024-08-05"},{"nctId":"NCT06531811","phase":"PHASE1","title":"A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-06","conditions":["Healthy Participants"],"enrollment":32,"completionDate":"2024-10-03"},{"nctId":"NCT04563533","phase":"PHASE1,PHASE2","title":"Clinical Trial of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2020-08-05","conditions":["Acute Gastroenteritis"],"enrollment":580,"completionDate":"2024-09-29"},{"nctId":"NCT06617130","phase":"NA","title":"The Efficacy of Amino Acid Supplementation in Treating Environmental Enteric Dysfunction Among Children At Risk of Malnutrition","status":"NOT_YET_RECRUITING","sponsor":"Kamuzu University of Health Sciences","startDate":"2024-11-01","conditions":["Amino Acid, Stunting, Environmental Enteric Dysfunction"],"enrollment":66,"completionDate":"2026-12-01"},{"nctId":"NCT05846568","phase":"PHASE3","title":"Study to Evaluate GR1801's Efficacy and Safety","status":"COMPLETED","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2022-10-21","conditions":["Rabies Post-exposure Prophylaxis"],"enrollment":1200,"completionDate":"2024-09-06"},{"nctId":"NCT06452563","phase":"PHASE4","title":"Amino Acids Supplementation and Exercise Intervention in Hemodialysis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mansoura University","startDate":"2024-05-12","conditions":["Hemodialysis Complication","Malnutrition"],"enrollment":100,"completionDate":"2024-09-30"},{"nctId":"NCT04973449","phase":"PHASE2,PHASE3","title":"Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-06-27","conditions":["COVID-19","SARS-CoV-2"],"enrollment":2843,"completionDate":"2022-08-02"},{"nctId":"NCT06072066","phase":"NA","title":"Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea","status":"RECRUITING","sponsor":"Integrative Skin Science and Research","startDate":"2023-11-22","conditions":["Rosacea","Systemic Inflammation"],"enrollment":24,"completionDate":"2024-12-31"},{"nctId":"NCT02145949","phase":"PHASE2","title":"Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults","status":"COMPLETED","sponsor":"University of Oregon","startDate":"2014-12","conditions":["Muscle Atrophy","Quality of Life"],"enrollment":80,"completionDate":"2020-02"},{"nctId":"NCT05110313","phase":"PHASE4","title":"Effects of Tildrakizumab on Epigenetic Age","status":"COMPLETED","sponsor":"Carlos Wambier","startDate":"2022-04-08","conditions":["Psoriasis","Aging","Epigenetic Disorder","Inflammation; Skin"],"enrollment":30,"completionDate":"2024-05-27"},{"nctId":"NCT04364230","phase":"PHASE1,PHASE2","title":"Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)","status":"COMPLETED","sponsor":"Craig L Slingluff, Jr","startDate":"2020-09-28","conditions":["Melanoma","Ocular Melanoma","Uveal Melanoma"],"enrollment":22,"completionDate":"2024-03-14"},{"nctId":"NCT04678830","phase":"PHASE2","title":"Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With \"Long\" COVID-19","status":"COMPLETED","sponsor":"CytoDyn, Inc.","startDate":"2021-03-01","conditions":["Coronavirus Disease 2019"],"enrollment":56,"completionDate":"2021-07-08"},{"nctId":"NCT06343272","phase":"NA","title":"Lymphocyte Enhancement in Gastroenteric Oncology","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-03-22","conditions":["Advanced Gastrointestinal Cancers"],"enrollment":54,"completionDate":"2025-02-28"},{"nctId":"NCT02737306","phase":"PHASE2","title":"A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation","status":"TERMINATED","sponsor":"CytoDyn, Inc.","startDate":"2017-05-14","conditions":["Graft Vs Host Disease"],"enrollment":11,"completionDate":"2021-09-30"},{"nctId":"NCT06282692","phase":"PHASE3","title":"INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2023-06-19","conditions":["COVID-19 Pandemic","COVID-19 Vaccines"],"enrollment":400,"completionDate":"2024-07-19"},{"nctId":"NCT05807204","phase":"NA","title":"Effect of a Multi-ingredient on Visceral Adiposity and Non-alcoholic Fatty Liver Disease in Individuals With Abdominal Obesity","status":"COMPLETED","sponsor":"Fundació Eurecat","startDate":"2023-05-01","conditions":["Visceral Obesity","Non-Alcoholic Fatty Liver Disease"],"enrollment":20,"completionDate":"2024-01-11"},{"nctId":"NCT06272253","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2023-09-19","conditions":["COVID-19 Pandemic","COVID-19 Vaccines"],"enrollment":250,"completionDate":"2024-07-19"},{"nctId":"NCT06125730","phase":"NA","title":"A Single-Group Study to Evaluate the Effects of an Eyelash Serum on Improving Eyelash Growth","status":"COMPLETED","sponsor":"Dime Beauty Co.","startDate":"2023-08-23","conditions":["Eyelash Growth"],"enrollment":35,"completionDate":"2024-02-10"},{"nctId":"NCT06259578","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2024-01-29","conditions":["COVID-19 Pandemic","COVID-19 Vaccines","COVID-19 Virus Disease"],"enrollment":400,"completionDate":"2024-12-29"},{"nctId":"NCT06235424","phase":"PHASE4","title":"Del Nido Versus HTK Cardioplegia in Adult Aortic Valve Replacement","status":"UNKNOWN","sponsor":"Medical University of Gdansk","startDate":"2018-10-01","conditions":["Aortic Valve Disease","Valve Disease, Heart","Cardiac Ischemia"],"enrollment":100,"completionDate":"2024-09-24"},{"nctId":"NCT06212765","phase":"PHASE3","title":"Oral Citrulline Supplementation in COPD Patients With Malnutrition","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2024-01-25","conditions":["Chronic Obstructive Pulmonary Disease Severe","Malnutrition"],"enrollment":60,"completionDate":"2026-09-25"},{"nctId":"NCT05714254","phase":"PHASE1","title":"Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-12-12","conditions":["Chronic Pain"],"enrollment":36,"completionDate":"2023-12-12"},{"nctId":"NCT04354259","phase":"PHASE2","title":"Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2020-05-13","conditions":["Sars-CoV2","Covid-19"],"enrollment":157,"completionDate":"2022-12-08"},{"nctId":"NCT06042764","phase":"PHASE2","title":"SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients","status":"UNKNOWN","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-08-31","conditions":["Infection of Upper Respiratory Tract Caused by 2019-nCoV"],"enrollment":150,"completionDate":"2024-08-30"},{"nctId":"NCT03172221","phase":"","title":"Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women","status":"COMPLETED","sponsor":"Foundation for Innovative New Diagnostics, Switzerland","startDate":"2017-07-25","conditions":["Plasmodium Falciparum","Pregnancy Malaria","Diagnoses Disease"],"enrollment":880,"completionDate":"2018-01-31"},{"nctId":"NCT04364750","phase":"EARLY_PHASE1","title":"Biomarkers of Diet-microbiota Interactions in Irritable Bowel Syndrome","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2021-07-15","conditions":["Irritable Bowel Syndrome"],"enrollment":30,"completionDate":"2024-04"},{"nctId":"NCT06048393","phase":"PHASE1","title":"SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People","status":"UNKNOWN","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-05-31","conditions":["COVID-19"],"enrollment":80,"completionDate":"2023-10-31"},{"nctId":"NCT03181893","phase":"PHASE2","title":"A Study In Adults With Moderate To Severe Dermatomyositis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-01-23","conditions":["Dermatomyositis"],"enrollment":75,"completionDate":"2022-11-28"},{"nctId":"NCT05918939","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-09-05","conditions":["COVID-19 Pandemic","COVID-19 Vaccines"],"enrollment":350,"completionDate":"2023-09-05"},{"nctId":"NCT05226429","phase":"PHASE1,PHASE2","title":"UNAIR Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-02-08","conditions":["COVID-19 Pandemic","Vaccine Reaction"],"enrollment":495,"completionDate":"2023-07-06"},{"nctId":"NCT05286359","phase":"NA","title":"Performance Evaluation of Malaria Plus Rapid Diagnostic Tests (RDTs) for the Detection of Plasmodium Infections in Patients With Symptoms Suggestive of Malaria","status":"COMPLETED","sponsor":"Abbott Rapid Dx","startDate":"2022-05-24","conditions":["Malaria"],"enrollment":1023,"completionDate":"2022-11-17"},{"nctId":"NCT04644484","phase":"PHASE3","title":"A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2020-09-23","conditions":["Rabies","Communicable Disease","Virus Diseases","Rhabdoviridae Infections","Mononegavirales Infections","RNA Virus Infections"],"enrollment":1000,"completionDate":"2022-12-16"},{"nctId":"NCT02740777","phase":"PHASE2","title":"Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females","status":"COMPLETED","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2016-02","conditions":["Human Papillomavirus","Cervical Intraepithelial Neoplasia","Persistent Infection"],"enrollment":900,"completionDate":"2019-07"},{"nctId":"NCT03596684","phase":"NA","title":"Citrulline Efficacy to Improve Carbohydrate Metabolism Abnormalities in the Patient Treated With High Doses of Statin","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2020-02-26","conditions":["Atorvastatin"],"enrollment":2,"completionDate":"2022-06-07"},{"nctId":"NCT05715944","phase":"PHASE3","title":"Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2","status":"COMPLETED","sponsor":"Botswana Harvard AIDS Institute Partnership","startDate":"2021-09-15","conditions":["COVID-19"],"enrollment":10888,"completionDate":"2022-12-30"},{"nctId":"NCT04343651","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19","status":"COMPLETED","sponsor":"CytoDyn, Inc.","startDate":"2020-04-01","conditions":["Coronavirus Disease 2019"],"enrollment":86,"completionDate":"2021-09-20"},{"nctId":"NCT02966314","phase":"PHASE4","title":"Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-03-30","conditions":["Idiopathic Angioedema"],"enrollment":12,"completionDate":"2020-01-06"},{"nctId":"NCT02592551","phase":"PHASE2","title":"MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2016-05-11","conditions":["Mesothelioma"],"enrollment":24,"completionDate":"2022-09-01"},{"nctId":"NCT05317117","phase":"NA","title":"Evaluating the Clinical Performance and Usability of Novel Malaria RDTs in Brazil","status":"UNKNOWN","sponsor":"PATH","startDate":"2022-07-04","conditions":["Malaria"],"enrollment":1030,"completionDate":"2022-12-31"},{"nctId":"NCT05508477","phase":"PHASE3","title":"UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-06-28","conditions":["COVID-19 Pandemic","COVID-19 Vaccines"],"enrollment":4005,"completionDate":"2023-05-28"},{"nctId":"NCT04656002","phase":"PHASE2","title":"As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2022-10","conditions":["Gastric Cancer"],"enrollment":43,"completionDate":"2024-12"},{"nctId":"NCT02924935","phase":"PHASE2,PHASE3","title":"Histidine Therapy: A Project to Treat HARS Deficiency","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2018-08-01","conditions":["HARS Syndrome"],"enrollment":14,"completionDate":"2022-12-31"},{"nctId":"NCT05042674","phase":"NA","title":"Clinical Study on Rapid Antioxidant Protection and Immune Modulating Effects.","status":"UNKNOWN","sponsor":"Natural Immune Systems Inc","startDate":"2021-09-20","conditions":["Pharmacokinetics"],"enrollment":24,"completionDate":"2023-05-05"},{"nctId":"NCT04967430","phase":"PHASE3","title":"TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-08-27","conditions":["Sars-CoV2","Covid19"],"enrollment":763,"completionDate":"2022-06-30"},{"nctId":"NCT02130882","phase":"PHASE2,PHASE3","title":"Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome","status":"UNKNOWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-05-19","conditions":["Respiratory System Agents","Anti-Asthmatic Agents","Hematologic Diseases","Leukocyte Disorders","Hypereosinophilia"],"enrollment":20,"completionDate":"2023-12-31"},{"nctId":"NCT02605525","phase":"PHASE2","title":"Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy","status":"WITHDRAWN","sponsor":"Baxalta now part of Shire","startDate":"2015-12-31","conditions":["Immunoglobulin A Nephropathy"],"enrollment":0,"completionDate":"2016-11-30"},{"nctId":"NCT04142294","phase":"NA","title":"Safety of Graded-Dose of Histidine in Humans","status":"COMPLETED","sponsor":"Cornell University","startDate":"2017-09-21","conditions":["Healthy"],"enrollment":40,"completionDate":"2019-08-31"},{"nctId":"NCT05211817","phase":"NA","title":"Research on Prevention, Intervention and Mechanisms of Obesity and Its Comorbidities","status":"UNKNOWN","sponsor":"Slovak Academy of Sciences","startDate":"2021-11-01","conditions":["Obesity","Exercise","Nutrition, Healthy"],"enrollment":60,"completionDate":"2023-12-31"},{"nctId":"NCT05176782","phase":"EARLY_PHASE1","title":"Comparison Between Histidine-tryptophan-ketoglutarate Cardioplegia and Cold Blood Cardioplegia for Myocardial Protection for Fallot Tetralogy Patients Undergoing Total Repair","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2021-12-15","conditions":["Anesthesia"],"enrollment":52,"completionDate":"2022-03-15"},{"nctId":"NCT02956317","phase":"PHASE1,PHASE2","title":"A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar","status":"COMPLETED","sponsor":"Sirnaomics","startDate":"2017-01","conditions":["Hypertrophic Scar"],"enrollment":25,"completionDate":"2018-01"},{"nctId":"NCT02859441","phase":"PHASE1,PHASE2","title":"A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2017-01-23","conditions":["Von Hippel-Lindau Syndrome"],"enrollment":3,"completionDate":"2019-07-09"},{"nctId":"NCT04764383","phase":"PHASE2","title":"Histaminergic Basis of Fatigue in Multiple Sclerosis","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2022-01-01","conditions":["Multiple Sclerosis"],"enrollment":0,"completionDate":"2022-10-30"},{"nctId":"NCT04117607","phase":"PHASE1","title":"Safety and Pharmacokinetics of Rezafungin","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-04","conditions":["Fungal Infection"],"enrollment":14,"completionDate":"2020-05-11"},{"nctId":"NCT02569632","phase":"PHASE4","title":"Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)","status":"COMPLETED","sponsor":"UCSF Benioff Children's Hospital Oakland","startDate":"2015-01","conditions":["Meningococcal Infections"],"enrollment":18,"completionDate":"2016-12"},{"nctId":"NCT02628951","phase":"PHASE2","title":"Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2016-05-26","conditions":["Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma"],"enrollment":62,"completionDate":"2019-01-02"},{"nctId":"NCT00811785","phase":"PHASE3","title":"Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency","status":"COMPLETED","sponsor":"Cyprium Therapeutics, Inc.","startDate":"2009-02-27","conditions":["Menkes Disease","Occipital Horn Syndrome","Unexplained Copper Deficiency"],"enrollment":93,"completionDate":"2020-08-28"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection, Paste","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"CLINIMIX"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"CLINIMIX E"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"ProcalAmine"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Travasol"},{"form":"INJECTION, EMULSION","route":"INTRAVENOUS","productName":"CLINIMIX"},{"form":"INJECTION, EMULSION","route":"INTRAVENOUS","productName":"Kabiven"},{"form":"INJECTION, EMULSION","route":"INTRAVENOUS","productName":"Perikabiven"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Clinisol"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Premasol - sulfite-free (Amino Acid)"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Aminosyn II"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Aminosyn-PF"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"FreAmine III"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"HepatAmine"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"ProSol"},{"form":"PASTE, DENTIFRICE","route":"DENTAL","productName":"CAREDO Treating Periodontitis Toothpastes100g"}]},"crossReferences":{"NUI":"N0000146980","MMSL":"NOCODE","NDDF":"004535","UNII":"4QD397987E","VUID":"4018669","CHEBI":"CHEBI:27570","VANDF":"4018669","INN_ID":"6163","RXNORM":"5340","UMLSCUI":"C0019602","chemblId":"CHEMBL1256578","ChEMBL_ID":"CHEMBL17962","KEGG_DRUG":"D00032","DRUGBANK_ID":"DB00117","PDB_CHEM_ID":" HIS","PUBCHEM_CID":"6274","SNOMEDCT_US":"60260004","IUPHAR_LIGAND_ID":"3310","MESH_DESCRIPTOR_UI":"D006639"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":49192,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"combinationProducts":[{"brandName":"Aminosyn II","ingredients":"alanine + arginine + aspartic acid + glutamic acid + glycine + histidine + isoleucine + leucine + lysine acetate + methionine + phenylalanine + proline + serine + threonine + tryptophan + valine"},{"brandName":"Aminosyn-PF","ingredients":"alanine + arginine + aspartic acid + glutamic acid + glycine + histidine + isoleucine + leucine + lysine acetate + methionine + phenylalanine + proline + serine + taurine + threonine + tryptophan + tyrosine + valine"},{"brandName":"CLINIMIX","ingredients":"alanine + arginine + glycine + histidine + isoleucine + leucine + lysine + methionine + phenylalanine + proline + serine + threonine + tryptophan + tyrosine + valine"},{"brandName":"CLINIMIX E","ingredients":"alanine + arginine + calcium chloride + glycine + histidine + isoleucine + leucine + lysine + magnesium chloride + methionine + phenylalanine + potassium phosphate, dibasic + proline + serine + sodium acetate + sodium chloride + threonine + tryptophan + tyrosine + valine"},{"brandName":"FreAmine III","ingredients":"alanine + arginine + cysteine + glycine + histidine + isoleucine + leucine + lysine acetate + methionine + phenylalanine + phosphoric acid + proline + serine + threonine + tryptophan + valine"},{"brandName":"HepatAmine","ingredients":"alanine + arginine + cysteine + glycine + histidine + isoleucine + leucine + lysine acetate + methionine + phenylalanine + phosphoric acid + proline + serine + threonine + tryptophan + valine"},{"brandName":"Kabiven","ingredients":"alanine + arginine + aspartic acid + calcium chloride + glucose + glutamic acid + glycine + histidine + isoleucine + leucine + lysine + magnesium sulfate + methionine + phenylalanine + potassium chloride + proline + serine + sodium acetate + sodium glycerophosphate + threonine + tryptophan + tyrosine + valine"},{"brandName":"Perikabiven","ingredients":"alanine + arginine + aspartic acid + calcium chloride + glucose + glutamic acid + glycine + histidine + isoleucine + leucine + lysine + magnesium sulfate + methionine + phenylalanine + potassium chloride + proline + serine + sodium acetate + sodium glycerophosphate + threonine + tryptophan + tyrosine + valine"},{"brandName":"ProSol","ingredients":"alanine + arginine + aspartic acid + glutamic acid + glycine + histidine + isoleucine + leucine + lysine acetate + methionine + phenylalanine + proline + serine + threonine + tryptophan + tyrosine + valine"},{"brandName":"ProcalAmine","ingredients":"alanine + arginine + calcium acetate + cysteine + glycerol + glycine + histidine + isoleucine + leucine + lysine acetate + magnesium acetate + methionine + phenylalanine + phosphoric acid + potassium chloride + proline + serine + sodium acetate + sodium chloride + threonine + tryptophan + valine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-08-17T00:00:00.000Z","mah":"OTSUKA ICU MEDCL","brand_name_local":null,"application_number":"NDA019398"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1994-07-11T00:00:00.000Z","mah":"OTSUKA ICU MEDCL","brand_name_local":null,"application_number":"NDA020015"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1999-04-15T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":"NDA020678"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2001-02-28T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":"ANDA020512"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2002-07-25T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":"NDA020734"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T01:32:23.063568+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}